Monument Re and AXA Belgium Agree the Transfer of a Run-off Life Insurance Portfolio
Monument Re, through its subsidiary Monument Assurance Belgium (MAB), and AXA Belgium have agreed today for the transfer of a run-off life insurance portfolio with BEGAAP provisions of EUR2.6bn, subject to regulatory approvals.
Koen Depaemelaere, CEO of Monument Assurance Belgium, said:
“We are pleased to announce this transaction that confirms Monument Assurance’s position as the leading consolidator in the Belgian market. It has been a pleasure to work with the AXA Belgium team. We look forward to welcoming the policyholders to Monument and would like to take the opportunity to assure them of our commitment to maintaining the high-quality service and security that they have enjoyed at AXA Belgium.”
Manfred Maske, CEO of Monument Re Group and Chairman of MAB, said:
“After the closing of the deal with Integrale last week, we are delighted to announce this transaction which fits perfectly with Monument’s consolidation strategy and confirms Belgium as a key target market for us. Following earlier acquisitions of six other Belgian portfolios this transaction with AXA Belgium continues that trajectory and affirms MAB’s position as the leading consolidator in the Belgian market.”
Monument Assurance Belgium (MAB) is a Belgian life assurance company regulated by the National Bank of Belgium. MAB is a member of the Monument Re Group and has established itself as the leading consolidator of life insurance and pension portfolios in Belgium.
Monument Re is a life insurance reinsurer and insurance holding company with a proven track record in acquiring capital-intensive European portfolios. Monument Re is present in Bermuda which, like Switzerland, is subject to requirements comparable to Solvency II in Europe. The Monument Re Group also operates through its subsidiaries in Belgium, the Netherlands, Ireland, Isle of Man, Guernsey, and Luxembourg, with branches in Spain, Italy, and Germany. Each entity is subject to local regulation and Monument Re is subject to Group Supervision by the Bermuda Monetary Authority.
Monument Re is backed by high-quality shareholders including Hannover Re, the world’s third largest reinsurer, Enstar, the industry’s largest non-life run-off consolidator listed on Nasdaq, and E-L Financial, the parent company of Canadian life insurer Empire Life.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For all media enquiries, please email: MAB@whyte.be (Célia Roger - 0478 82 74 70)
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shippeo Advances Multimodal Transport Visibility Platform With New Autumn Platform Release, Announces Searoutes Partnership for Precise Carbon Emissions Tracking7.12.2022 11:54:00 CET | Press release
Shippeo, a leading provider of global and multimodal shipment visibility, announced major platform enhancements as part of their feature-packed 2022 Autumn platform release at their Visibility Now! event in Paris. The update brings a range of new, disruptive capabilities to their Ocean Visibility solution, higher accuracy carbon emissions calculations powered by specialist Searoutes, and a range of general enhancements aimed at boosting data quality, usability and supply chain ecosystem collaboration. “We know that supply chain resiliency is top of mind for supply chain executives and that dynamic operational visibility is foundational for resilience,” explains Anand Medepalli, Chief Product Officer at Shippeo. “Our latest platform release brings a range of exciting features and capabilities, arming organizations with the tools and knowledge to make quicker decisions, mitigate disruptions and collaborate with trading partners in real time, so that supply chain actors can design, plan a
Tech Mahindra Launches Cloud BlazeTech to Maximize Business Value for Cloud-Powered Enterprises Globally7.12.2022 11:30:00 CET | Press release
Tech Mahindra, a leading provider of digital transformation, consulting, and business re-engineering services and solutions, today announced the launch of Cloud BlazeTech, an integrated, sector-agnostic platform, to maximize business value for cloud-powered enterprises globally. The organization will continue to invest in cloud services & hyperscaler relationships to boost digital transformation for enterprises. Integrated cloud migration, cloud-native operation & self-healing governance model, "Cloud BlazeTech" supports bi-modal infrastructure transformation and helps enterprises to accelerate to a cloud-native world. In addition, the platform has integrations with hyperscaler hybrid cloud platforms to provide industry-specific pre-build cloud-native solutions that drive faster business outcomes. By adopting the Cloud BlazeTech platform, enterprises will achieve 25-30% cost savings and a 30% improvement in migration time. Sudhir Nair, Chief Delivery Officer & Global Head – Infra & Clo
Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes7.12.2022 10:39:00 CET | Press release
The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes.1 When empagliflozin was added to other baseline treatments (diet, exercise, metformin and/or insulin) HbA1c was reduced by 0.84% compared with placebo at week 26 (95% CI –1.50 to –0.19; P=0.012).1 The results were presented today at the International Diabetes Federation (IDF) World Diabetes congress 20221, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005405/en/ The DINAMO (DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents) trial included youth aged 10-17 years with type 2 diabetes and HbA1c ≥6.5% and ≤10.5%. Participants were randomly assigned treatmen
Opening Ceremony Held for NTHU’s Center for Dissection Education and Research7.12.2022 10:00:00 CET | Press release
The opening ceremony for National Tsing Hua University (NTHU) in Taiwan’s Center for Dissection Education and Research, which cost over NT$100 million, was recently held. The ceremony included a memorial service for the cadaver donors. As an expression of gratitude, the first batch of students in the Post-baccalaureate Program in Medicine also offered Chinese bellflowers to the donors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221207005054/en/ Students of the Post-baccalaureate Program in Medicine at NTHU offering Chinese bellflowers to those who have donated their cadavers to the program. (Photo: National Tsing Hua University) At the ceremony, former NTHU president Hocheng Hong signed the first donation agreement, which indicates that the donor has unconditionally pledged his body for education and research after death, for the purposes of advancing medical science. Current NTHU president W. John Kao thanked Hocheng fo
BIOCORP Obtains 510(k) FDA Clearance for Mallya ®7.12.2022 07:30:00 CET | Press release
Regulatory News: BIOCORP (FR0012788065 – ALCOR / Eligible PEA‐PME), a French company specialized in the design, development, and manufacturing of innovative medical devices, announced today that they have received 510(K) clearance from the U.S. Food & Drug Administration (FDA) to market Mallya, its smart medical device that connects insulin pens. Eric Dessertenne, CEO of BIOCORP, said: "This approval is a major achievement for BIOCORP and all of our employees who have been heavily involved in this regulatory process. This approval marks a historic achievement for BIOCORP as it allows the commercial launch of our Mallya device in the United States and illustrates BIOCORP's ability to meet the highest regulatory requirements. This news has been eagerly awaited by all our industry partners to commercialize Mallya in the world's largest diabetes market and we are delighted that U.S. patients will soon be able to benefit from Mallya's services. This regulatory milestone will have a positive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom